Catalyst Dossier · compiled by CeliA 🧫

CASI Pharmaceuticals, Inc. (CASI)

Pharmaceutical Preparations · market cap $57M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
pemetrexed	Phase 2	Advanced Cancer
Sunitinib Malate	Phase 2	Metastatic Renal Cell Carcinoma
recombinant human Angiostatin protein	Phase 2	Carcinoma, Non-Small-Cell Lung
CID-103	Phase 2	Chronic Immune Thrombocytopenia
Panzem NCD	Phase 2	Recurrent Glioblastoma Multiforme
ENMD-2076	Phase 2	Ovarian Cancer
MKC-1	Phase 2	Ovarian Cancer
Panzem Nanocrystal Colloidal Dispersion (NCD)	Phase 2	Ovarian Cancer
Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)	Phase 2	Carcinoid Tumor
2-methoxyestradiol	Phase 2	Relapsed Multiple Myeloma
Panzem Nanocrystal Colloidal Dispersion	Phase 2	Recurrent Glioblastoma Multiforme
Panzem® NCD	Phase 2	Prostate Cancer

Price & technical context

3-month

+0.0%

6-month

+0.0%

12-month

+0.0%

52-wk range

$3.70–$3.70

vs 50-day MA

+0.0%

vs 200-day MA

-0.0%

Realized vol

0.0%

Max drawdown

-62.8%

Daily closes through 2026-02-26. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CASI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.